
    
      Use of glucosamine and chondroitin have been associated with reduced cancer and overall
      mortality. The aim of this study is to determine whether a common starting dose of
      glucosamine and chondroitin (1500 mg/d + 1200 mg/d, respectively) reduces systemic
      inflammation as reflected by a reduction in high sensitivity C-reactive protein.
    
  